Twist Bioscience Corporation (TWST) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $91.66 (+0.42%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Luke Sergott | Barclays | $55.00 | -40.0% |
| Nov 3, 2025 | Steven Etoch | Stephens | $41.00 | -55.3% |
| May 6, 2025 | Catherine Ramsey Schulte | Robert W. Baird | $44.00 | -52.0% |
| Feb 4, 2025 | Catherine Ramsey Schulte | Robert W. Baird | $54.00 | -41.1% |
| Feb 3, 2025 | Luke Sergott | Barclays | $58.00 | -36.7% |
| Sep 17, 2024 | Catherine Schulte | Robert W. Baird | $46.00 | -49.8% |
| Jun 5, 2024 | Subbu Nambi | Guggenheim | $53.00 | -42.2% |
| May 3, 2024 | Catherine Ramsey Schulte | Robert W. Baird | $40.00 | -56.4% |
| Jan 17, 2024 | Matthew Sykes | Goldman Sachs | $45.00 | -50.9% |
| Feb 5, 2023 | Luke Sergott | Barclays | $32.00 | -65.1% |
| Oct 6, 2022 | Luke Sergott | Barclays | $45.00 | -50.9% |
Top Analysts Covering TWST
TWST vs Sector & Market
| Metric | TWST | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +5.0% | +16366.1% | +18.0% |
| P/E Ratio | -47.18 | 3.05 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $437M | $439M | $440M | 6 |
| 2026-12-31 | $118M | $119M | $120M | 2 |
| 2027-03-31 | $123M | $124M | $125M | 2 |
| 2027-06-30 | $127M | $128M | $129M | 2 |
| 2027-09-30 | $131M | $132M | $133M | 2 |
| 2027-12-31 | $136M | $138M | $138M | 2 |
| 2028-03-31 | $141M | $143M | $143M | 1 |
| 2028-06-30 | $145M | $146M | $147M | 1 |
| 2028-09-30 | $151M | $152M | $153M | 1 |
| 2029-09-30 | $655M | $663M | $669M | 4 |
| 2030-09-30 | $753M | $762M | $769M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-1.80 | $-1.67 | $-1.53 | 4 |
| 2026-12-31 | $-0.33 | $-0.33 | $-0.33 | 1 |
| 2027-03-31 | $-0.34 | $-0.33 | $-0.33 | 1 |
| 2027-06-30 | $-0.28 | $-0.28 | $-0.28 | 1 |
| 2027-09-30 | $-0.23 | $-0.23 | $-0.23 | 1 |
| 2027-12-31 | $-0.21 | $-0.21 | $-0.21 | 1 |
| 2028-03-31 | $-0.19 | $-0.19 | $-0.19 | 1 |
| 2028-06-30 | $-0.14 | $-0.14 | $-0.14 | 1 |
| 2028-09-30 | $-0.09 | $-0.09 | $-0.09 | 1 |
| 2029-09-30 | $0.49 | $0.49 | $0.50 | 3 |
| 2030-09-30 | $1.22 | $1.24 | $1.25 | 2 |
Frequently Asked Questions
What is the analyst consensus for TWST?
The consensus among 14 analysts covering Twist Bioscience Corporation (TWST) is Buy with an average price target of $89.11.
What is the highest price target for TWST?
The highest price target for TWST is $58.00, set by Luke Sergott at Barclays on 2025-02-03.
What is the lowest price target for TWST?
The lowest price target for TWST is $32.00, set by Luke Sergott at Barclays on 2023-02-05.
How many analysts cover TWST?
14 analysts have issued ratings for Twist Bioscience Corporation in the past 12 months.
Is TWST a buy or sell right now?
Based on 14 analyst ratings, TWST has a consensus rating of Buy (2.00/5) with a +5.0% upside to the consensus target of $89.11.
What are the earnings estimates for TWST?
Analysts estimate TWST will report EPS of $-1.67 for the period ending 2026-09-30, with revenue estimated at $439M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.